Sanofi India’s third quarter results are announced in real time: profit fell 45.89% year-on-year

Sanofi India's third quarter results are announced in real time: profit fell 45.89% year-on-year

2024-11-08 12:15:18 :

Sanofi India third quarter results live broadcast: Sanofi India announced its third quarter results on November 7, 2024, with both revenue and profit declining significantly. The company’s revenue fell by 26.67% year-on-year, and its profits dropped significantly by 45.89% from the same period last year.

Compared with the previous quarter, Sanofi India’s revenue increased by 13.05% and its profit decreased by 20.35%. This suggests a mixed performance, with some recovery on a quarter-on-quarter basis despite year-over-year declines.

The company’s selling expenses, general expenses and administrative expenses showed a positive trend, falling 5.81% month-on-month and 39.16% year-on-year. The reduction in expenses may provide some relief amid declining revenue.

Operating income in the third quarter increased by 3.75% month-on-month, but still dropped significantly by 44.18% year-on-year. This points to challenges in maintaining profitability despite cost-cutting measures.

Earnings per share (EPS) also took a hit, at $In the third quarter, it was 35.69, a year-on-year decrease of 45.88%. This decline may worry investors as it reflects the overall profitability challenges facing the company.

Looking at stock performance, Sanofi India returned -3.48% over the past week. However, the company has returned 29.46% over the past six months and 29.96% year-to-date, suggesting resilience over the long term despite recent volatility.

As of November 8, 2024, Sanofi India’s market capitalization was $15,103.14 Crore and the 52-week trading range is $4,694.05 and $7,600. This range reflects the market’s volatile sentiment toward the company’s performance.

Analyst sentiment appears cautiously optimistic, with two-thirds recommending a buy rating and one analyst assigning a strong buy rating. As of November 8, 2024, the consensus recommendation is “Strong Buy,” indicating the potential for recovery.

Get the latest updates on quarterly results with our results calendar

Follow us On Social Media   Twitter/X

Join WhatsApp

Join Now

---Advertisement---